BACK TO TOP
KSE100
171,115.82
-1778.45
(-1.03%)
KSE100PR
52,304.80
-552.93
(-1.05%)
ALLSHR
102,630.81
-743.98
(-0.72%)
KSE30
51,478.54
-641.56
(-1.23%)
KMI30
245,731.79
-3035.82
(-1.22%)
BKTI
47,279.59
-660.98
(-1.38%)
OGTI
35,704.94
-598.06
(-1.65%)
KMIALLSHR
66,650.31
-541.20
(-0.81%)
PSXDIV20
79,163.91
-560.90
(-0.70%)
UPP9
60,585.65
-695.66
(-1.14%)
NITPGI
45,586.52
-569.04
(-1.23%)
NBPPGI
49,531.01
-637.85
(-1.27%)
MZNPI
30,235.06
-350.90
(-1.15%)
JSMFI
42,097.48
-354.64
(-0.84%)
ACI
22,609.69
-253.52
(-1.11%)
JSGBKTI
72,548.24
-1005.30
(-1.37%)
HBLTTI
18,330.55
07-05-2026
5.87
(0.03%)
MII30
22,197.30
-240.89
(-1.07%)
BF Biosciences Limited
PHARMACEUTICALS
Rs.139.93
-3.93
(-2.73%)
1D
1M
6M
YTD
1Y
3Y
5Y
^ As of Fri, May 8, 2026 4:39 PM
REG
DFC
CSF
ODL
Open
143.00
High
143.00
Low
139.50
Volume
325,307
CIRCUIT BREAKER
129.47 — 158.25
DAY RANGE
139.50 — 143.00
52-WEEK RANGE ^
117.00 — 194.90
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0
LDCP
143.86
VAR
12.50
HAIRCUT
17.50
P/E Ratio (TTM) **
22.25
1-Year Change * ^
14.30%
YTD Change * ^
-0.42%

No record found

Last update: Sun, Apr 26, 2026 8:32 AM
Open
0.00
High
0.00
Low
0.00
Close
0.00
Change
0.00%
LDCP
149.19
Volume
0
Total Trades
0
CIRCUIT BREAKER
134.27 — 164.11
DAY RANGE
0.00 — 0.00
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0
Last update: Sun, Mar 29, 2026 4:05 AM
Open
0.00
High
0.00
Low
0.00
Close
0.00
Change
0.00%
LDCP
147.00
Volume
0
Total Trades
0
CIRCUIT BREAKER
132.30 — 161.70
DAY RANGE
0.00 — 0.00
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0
Last update: Sun, Mar 1, 2026 2:44 AM
Open
0.00
High
0.00
Low
0.00
Close
0.00
Change
0.00%
LDCP
145.24
Volume
0
Total Trades
0
CIRCUIT BREAKER
130.72 — 159.76
DAY RANGE
0.00 — 0.00
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0

No record found

Market data powered by capitalstake.com. Provided by PSX. ** Based on unconsolidated financials
  * Returns not adjusted for payouts
  ^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.

Company Profile

BUSINESS DESCRIPTION

BF Biosciences Limited ("BFBL", "Company", or the "Issuer") was incorporated as an unlisted public limited company under the Companies Ordinance, 1984 (now Companies Act, 2017) in 2006, and operates within the pharmaceutical industry. BFBL is a 80%:20% joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina. The Company's core operations involve the import, manufacturing, marketing and distribution of pharmaceutical products.

KEY PEOPLE
Akhter Khalid WaheedCEO
Sebastian Martin FerrarassiChairperson
Abdur RehmanCompany Secretary
ADDRESS

197-A, The Mall, Rawalpindi, Pakistan

WEBSITE

www.bfbio.com

REGISTRAR

CDC Share Registrar Services Limited, CDC House, 99-B, Block-B, S.M.C.H.S, Main Shahrah Faisal, Karachi

AUDITOR

KPMG Taseer Hadi & Co. Chartered Accountants

Fiscal Year End

June

Equity Profile

Market Cap (000's)
12,360,483.43
Shares
88,333,334
Free Float
26,500,000
Free Float
30.00%

Announcements

Financial Results
Board Meetings
Others
DateTitleDocument
Apr 30, 2026Transmission of Quarterly Report for the Period Ended 31-03-2026 View   PDF
Apr 28, 2026Financial Results for the Quarter Ended 31-03-2026 View   PDF
Apr 17, 2026Half Yearly Progress Report - For the Period Ended 31 December 2025 View   PDF
Feb 27, 2026Transmission of Quarterly Financial Statements for the Period Ended 31-12-2025 View   PDF
Feb 26, 2026Financial Results for the Quarter Ended 31-12-2025 View   PDF
DateTitleDocument
Apr 20, 2026Board Meeting View   
Feb 18, 2026Board Meeting View   
Dec 22, 2025Decisions of Emergent Board of Directors Meeting Held On Dec 19, 2025 View   PDF
Dec 18, 2025Emergent Board Meeting Other Than Financial Results View   
Oct 27, 2025Certified true copy of the resolutions passed in the Annual General Meeting of the Company View   PDF
DateTitleDocument
Mar 4, 2026Resignation of Director View   PDF
Nov 20, 2025Corporate Briefing Session - Presentation View   PDF
Nov 18, 2025Corporate Briefing Session View   PDF
Oct 14, 2025Material Information View   PDF
Oct 13, 2025Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   

Financials

All numbers in thousands (000's) except EPS

Annual
Quarterly
2025
Sales5,837,466
Profit after Taxation447,147
EPS5.52
Q3 2026Q2 2026Q1 2026Q3 2025
Sales2,135,4912,668,1252,432,2941,500,469
Profit after Taxation117,646187,782159,521124,527
EPS1.332.131.811.59
Data powered by Capital Stake. To provide comparable data, information might have been standardized. The data presented may therefore differ from issuer's annual report and 'as reported' data should be obtained directly from the source issuer. See the Capital Stake Terms of Use.

Ratios

202520242023
Gross Profit Margin (%)39.1941.89
Net Profit Margin (%)7.6610.53
EPS Growth (%)(9.36)
PEG(3.27)

Payouts

Financial Reports